X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 0.00 shares.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was 0.00 shares.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 2.03K shares, a 65.34% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 5.86K shares, a 66.87% decline from fiscal 2020.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 17.69K shares, a 65.73% decline from fiscal 2019.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 51.62K shares, a 89.59% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-12-31 | 2.03K shares 10-K · filed 2024-03-21 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 5.86K shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 5.86K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 10.14K shares derived: sum of 4 quarters · filed 2021-08-03 |
| 2021-03-31 | 5.86K shares 10-Q · filed 2021-05-06 | 10.54K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | 17.69K shares 10-K · filed 2021-03-19 |
| 2020-09-30 | 4.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 43.68K shares derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | 407.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | 47.85K shares derived: sum of 4 quarters · filed 2020-08-04 |
| 2020-03-31 | 13.01K shares 10-Q · filed 2020-05-07 | 48.14K shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 25.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | 51.62K shares 10-K · filed 2020-03-12 |
| 2019-09-30 | 8.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 31.83K shares derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | 700.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 23.38K shares derived: sum of 4 quarters · filed 2019-08-07 |
| 2019-03-31 | 16.48K shares 10-Q · filed 2019-05-15 | |
| 2018-12-31 | 6.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | 27.23K shares 10-K · filed 2019-03-11 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |